Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,725,786 papers from all fields of science
Search
Sign In
Create Free Account
RC 160
Known as:
RC-160
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
vapreotide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Lipophilization of somatostatin analog RC‐160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro
P. Dasgupta
,
R. Mukherjee
British Journal of Pharmacology
2000
Corpus ID: 25156265
The therapeutic potential of the somatostatin analogue RC‐160 having antiproliferative activity, is limited by its short serum…
Expand
1999
1999
Lipophilization of Somatostatin Analog RC-160 Improves Its Bioactivity and Stability
P. Dasgupta
,
A. T. Singh
,
R. Mukherjee
Pharmaceutical Research
1999
Corpus ID: 24096742
AbstractPurpose. Acromegaly is a symptomatically disabling condition, resulting from a growth hormone (GH) secreting pituitary…
Expand
Highly Cited
1992
Highly Cited
1992
Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and…
S. Milovanović
,
S. Radulović
,
K. Groot
,
A. Schally
The Prostate
1992
Corpus ID: 27861576
The effects of treatment with a bombesin receptor antagonist [D‐Tpi6, Leu13Ψ(CH2NH) Leu14]BN(6–14)(RC‐3095) and the combination…
Expand
1992
1992
Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC‐160
Yunfeng Qin
,
A. Schally
,
G. Willems
International Journal of Cancer
1992
Corpus ID: 39563687
Hepatic metastases of colon 320 DM and WidR human colon cancers in nude mice were treated by s.c. injections of somatostatin…
Expand
Review
1992
Review
1992
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
A. Schally
,
A. Comaru-Schally
,
D. González-Bárcena
Biomedicine & pharmacotherapy = Biomedecine…
1992
Corpus ID: 29492713
1989
1989
Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
A. Zalatnai
,
A. Schally
Cancer Research
1989
Corpus ID: 39917824
Antitumoral effects of the agonist of luteinizing hormone-releasing hormone (D-Trp-6-LH-RH) and the somatostatin analog RC-160 (D…
Expand
1989
1989
Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160
A. Zalatnai
,
A. Schally
International Journal of Pancreatology
1989
Corpus ID: 25487024
]SummaryThe effect of treatment with D-Trp-6-LH-RH, an agonist of luteinizing hormone-releasing hormone (LHRH), and somatostatin…
Expand
1988
1988
Comparison of Somatostatin and Its Highly Potent Hexa- and Octapeptide Analogs on Exocrine and Endocrine Pancreatic Secretion
S. Konturek
,
J. Bilski
,
J. Jaworek
,
J. Tasler
,
A. Schally
Proceedings of the Society for Experimental…
1988
Corpus ID: 38438026
Abstract The effects on pancreatic responses of highly potent cyclic hexapeptide (cyclo (N-Me-Ala-Phe-D-Trp-Lys-Thr-Phe)) (Veber…
Expand
1987
1987
Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.
T. Karashima
,
R. Cai
,
A. Schally
Life Science
1987
Corpus ID: 13058010
Highly Cited
1987
Highly Cited
1987
Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
J. Paz‐Bouza
,
T. Redding
,
A. Schally
Proceedings of the National Academy of Sciences…
1987
Corpus ID: 3216133
Pancreatic ductal adenocarcinoma was induced in female Syrian golden hamsters by injecting N-nitrosobis(2-oxopropyl)amine (BOP…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE